Sandoz Recalls Antacid In Another Generics Firestorm
The Novartis unit moved to recall all lots of ranitidine capsules in the US due to confirmed contamination with NDMA.
You may also be interested in...
Consumer health and cosmetic product recalls added to FDA database on 18 and 25 September also include lidocaine topicals Ridge Properties provides for use in OTC products marketed as pre-tattoo prep or for pain or itch relief after the products were found to be contaminated and above specification for lidocaine assay.
Novartis, which licensed OTC Zantac for US marketing to Sanofi, stops distribution of the histamine-2 blocker ranitidine to presence of NDMA, a probable carcinogen. Decision doesn’t affect US sales of OTC Zantac in US, where FDA says NDMA found in ingredient is at low levels.
Pharmacy petitions for recalls after finding ‘inherent instability’ in antacid that could pose carcinogenic risk.